Skip to content

NASDAQ · large · thesis board

VRTX Vertex Pharmaceuticals

CF franchise + gene editing partnerships

View race

Thesis

Editorial summary — not a primary filing

CF cash cow funding pain, SCD (Casgevy partner), and kidney programs.

Next gate

2026-09-05Company-guidedlabel expand

SCD access update

23 days · Company: Company guidance

Survive-to-Event

ok

Cash covers the next gate with ~28 months spare (curated estimate).

Unverified estimate — not from a live SEC parse

Cash runway (~869d)100%
Days to gate (23d)3%
Show math

$10.0B cash ÷ $350M/mo burn ≈ 869 days. Source: curated SEC quarter figures.

Cash $10.0B as of 2026-03-31 (SEC)

Pipeline spine

  1. Preclinical
  2. Ph1
  3. Ph2
  4. Ph3
  5. Filed
  6. Approved

Rivals in this race

Open race →
CRSPApprovedokBLUEApprovedokEDITPh2ok

Risks

  • Pipeline diversification
  • Pain program risk
  • Competition
  • Pricing

Source trail

  1. SECCash from latest reported quarter (curated)as of 2026-03-31
  2. ClinicalTrials.govNCT03745287as of 2026-07-01
  3. CompanyIR / press disclosuresas of 2026-07-01